This company listing is no longer active
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております！
Aceragen マネジメント
マネジメント 基準チェック /34
Aceragen's CEO is John Taylor, appointed in Sep 2022, he has a tenure of less than a year. His total yearly compensation is $444.06K , comprised of 17.5% salary and 82.5% bonuses, including company stock and options. He directly owns 17.45% of the company’s shares, worth $558.40K. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
主要情報
John Taylor
最高経営責任者
US$444.1k
報酬総額
| CEO給与比率 | 17.5% |
| CEO在任期間 | less than a year |
| CEOの所有権 | 17.5% |
| 経営陣の平均在職期間 | 4.1yrs |
| 取締役会の平均在任期間 | 4.3yrs |
経営陣の近況
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$444k | US$78k | -US$23m |
報酬と市場: John's total compensation ($USD444.06K) is below average for companies of similar size in the US market ($USD760.57K).
報酬と収益: Insufficient data to compare John's compensation with company performance.
CEO（最高経営責任者
John Taylor (52 yo)
less than a year
在職期間
US$444,062
報酬
Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Associate Director of Human Resources | no data | データなし | データなし | |
| Director of Human Resources | no data | データなし | データなし | |
| Senior Vice President of Technical Operations | no data | データなし | データなし | |
| Global Head of Quality | no data | データなし | データなし | |
| Medical Director & Global Clinical Lead for Oncology | no data | データなし | データなし | |
| Advisor | 4.1yrs | US$993.93k | データなし | |
| Adviser | no data | US$986.13k | データなし |
4.1yrs
平均在職期間
62yo
平均年齢
経験豊富な経営陣: ACGN's management team is considered experienced (4.1 years average tenure).
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Independent Director | 4.3yrs | US$89.43k | 0.26% $ 8.4k | |
| Chair of the Board of Directors | 8.7yrs | US$1.43m | 0.10% $ 3.2k | |
| Independent Director | less than a year | US$11.88k | データなし | |
| Independent Director | 7.6yrs | US$66.24k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$60.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisor Board | no data | データなし | 14.31% $ 458.0k |
4.3yrs
平均在職期間
63.5yo
平均年齢
経験豊富なボード: ACGN's board of directors are considered experienced (4.3 years average tenure).